All content for The Business of Eye Innovation is the property of Medevise Consulting and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The podcast that explores insight, trends and opinion in the business of European ophthalmology.
Episode 14 - Two Years of Medevise: A Conversation with the Medevise Board
The Business of Eye Innovation
22 minutes 31 seconds
2 years ago
Episode 14 - Two Years of Medevise: A Conversation with the Medevise Board
On this episode of the BOEI Podcast, the Medevise board of directors takes a look back over the last two years since the company was founded to reflect on the original mission, the market need that Medevise fills, its rapid growth, and the vision for what’s next.
Speakers:
Kristine Morrill, Founder and President of Medevise Consulting
Paul Bikard, Chief Financial Officer
Bernie Haffey, Board Member
Michael Mrochen, Board Member
Vance Thompson, Board Member
Tom Ruggia, Board Member
Board member not present: Gerd Auffarth
Key Takeaways:
The Medevise board discussed the original promise of Medevise when it was founded in 2021, and what factors led the board members to commit to the company:
Medevise addresses the biggest challenges that the board members have seen companies falter on and eventually fail
Unmet market need: There are other businesses that provide each one of our primary services individually (market access and reimbursement, clinical and the regulatory, and communications), but there's no other group in the world doing all of them together
High-level expertise in each discipline providing and business perspective, clinical perspective, regulatory perspective, clinician perspective
Companies can access that expertise very quickly to address their specific need
Medevise has the experience and processes to manage the complexity of the European market, including differing regulatory environments, and cultural and communications nuances.
Committed to a high performance management system for strategic and intentional growth and operations
Full-time dedicated staff
Central point of contact for consolidated European market strategy and execution, rather than a complex network of multiple partners / distributors / regulatory opinions
The board also considered what they envision in Medevise’s future:
Continued growth on the current foundation, and as global expansions become more complex, continuing to serve as a European partner for faster and smoother go-to-market
Serving medical device markets outside the reimbursed system
Learn more about the Medevise board on our website. For more engaging topics on medical device innovation, please follow Medevise on LinkedIn.
The Business of Eye Innovation
The podcast that explores insight, trends and opinion in the business of European ophthalmology.